Literature DB >> 10706688

Role of activator protein-1 in TCR-mediated regulation of the murine fasl promoter.

K Matsui1, S Xiao, A Fine, S T Ju.   

Abstract

The present study demonstrates that transcription factor interactions are important in regulating the murine fasl promoter following TCR-mediated activation. We used DNase I-footprinting, EMSAs, and transient transfection assays to identify the minimal TCR signal-responsive region within the fasl promoter. This region contains the previously identified binding sites for NF-kappaB and Egr and the AP-1 site identified in this study. We found that TCR signaling induces AP-1 binding to this site and regulates the fasl promoter function in a fashion dependent on NF-kappaB binding. However, mutation in the AP-1 site alone did not show a significant effect on the promoter function. The data suggest that the minimal promoter required at least two transcription factors to function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706688     DOI: 10.4049/jimmunol.164.6.3002

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

1.  A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.

Authors:  S T Eichhorst; M Müller; M Li-Weber; H Schulze-Bergkamen; P Angel; P H Krammer
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses.

Authors:  Nathalie M Droin; Michael J Pinkoski; Emmanuel Dejardin; Douglas R Green
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 3.  Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses.

Authors:  Madhu Ramaswamy; Sophia Y Cleland; Anthony C Cruz; Richard M Siegel
Journal:  Results Probl Cell Differ       Date:  2009

Review 4.  Targeting HOX/PBX dimers in cancer.

Authors:  Richard Morgan; Mohamed El-Tanani; Keith D Hunter; Kevin J Harrington; Hardev S Pandha
Journal:  Oncotarget       Date:  2017-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.